Manufacturing, Cell Culture and Fermentation

Fujifilm’s center adds local support in Suzhou, China for cell culture media optimization.

Sartorius will invest approximately €270 million (US$305 million) to expand its biopharmaceutical manufacturing activities in South Korea’s biopharm hub.

Lonza is expanding its microbial development capabilities at its Visp, Switzerland, site to support clinical and commercial drug development programs.

Fujifilm is expanding its R&D footprint at its California facility.

The adoption of perfusion cell culture continues to advance with the help of PAT tools.

Advancements in bioprocessing technologies test microbial fermentation adaptability.

Corning’s new Ascent fixed bed reactor (FBR) system is an automated bioproduction platform designed to significantly improve yields and reduce bioproduction costs.

Automation is one asset that benefits cell harvesting by cutting out laborious manual steps and minimizing contamination.

The companies work to develop and supply advanced cell models that better reflect an in-vivo environment to improve drug discovery accuracy and efficiency.

Cell-free expression is promising in preclinical applications, but still presents challenges to scale up for commercial production.

Originally established in the 1970s as a fetal bovine serum supplier, Fujifilm Irvine Scientific continuously proved its strength in the cell culture solutions space.

Demand for recombinant microorganism-based cell culture supplements is rising on the back of lower contamination risk.

The innovation of single-use technologies is applicable early on in the manufacturing process.

The new facility, which is expected to be operational by spring 2025, will feature 8 x 20,000-L bioreactors with the potential to add further 24 x 20,000-L bioreactors based on market demand.

Using the capabilities of Pharma Waldhof, one of Aceto’s facilities in Düsseldorf, Germany, the company plans to provide customers with access to raw materials, tested products for pharmaceutical cell culture applications, and cell culture media ingredients.

Overcoming time and cost constraints can help enable seed train intensification efforts to maximize product yield.

The new facility, which will be operated by Fujifilm Diosynth Biotechnologies, will provide large-scale cell-culture manufacturing of bulk drug substance with 8 x 20,000-L bioreactors.

Cell-culture optimization may see benefits from a synthetic biology-based approach that improves product titer, quality, and time.

Samsung Biologics has adopted Solentim’s cell seeding and cell metric platforms at its new R&D center in San Francisco, CA.

Mogrify’s new technology platform, EpiMOGRIFY, can predict cellular switches important for determining cell identity, cell maintenance, directed differentiation, and cell conversion.

The new VirusExpress lentiviral production platform increases dose yields and reduces process development time for cell and gene therapies.

Bioreactor technology advances can offer seamless manufacturing scale-up and can reduce the timeline and cost of biologics production.

The investment will include new manufacturing lines and increased automation to deliver additional manufacturing capacity.

The company has made several moves in recent weeks to expand manufacturing capacity and cell line services.

Innovative approaches, including ready-to-use materials and in-line dilution, can significantly streamline overall bioprocessing operations.

Advanced data analytics, including statistical modeling and machine learning technique, can enable more efficient and reliable bioprocesses.

Better understanding and control of cell behavior is yielding benefits, upstream and beyond.

The future of raw material sourcing for mAb production may lay in the sustainability of the source and the added benefits of newer technologies.

The production of viral vectors for use in gene therapy benefits from being able to use similar cell-culture processes as mAbs, but it faces limitations under current cell-culture technologies.

Industry experts debate the pros and cons of “going bigger” than the 2000-L industry norm in a single vessel.